Stock Events

Terns Pharmaceuticals 

$7.41
19
-$0.47-6.03% Thursday 20:00

Statistics

Day High
7.76
Day Low
7.26
52W High
11.4
52W Low
3.26
Volume
1,841,790
Avg. Volume
1,937,315
Mkt Cap
536.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

6
NOV
Earnings
 

Earnings

6NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.42
-0.36
-0.31
-0.25
Expected EPS
-0.335981
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TERN. It's not an investment recommendation.
Alphabet
77346
GOOGL
Apple
67415
AAPL
Microsoft
62824
MSFT
Amazon
58558
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences is a leading biopharmaceutical company that competes with Terns Pharmaceuticals in the development of treatments for liver diseases, including NASH, which is a focus area for Terns.
Madrigal Pharmaceuticals
MDGL
Mkt Cap5.37B
Madrigal Pharmaceuticals focuses on the development of therapies for cardiovascular, metabolic, and liver diseases, including NASH, directly competing with Terns Pharmaceuticals' interests.
Viking Therapeutics
VKTX
Mkt Cap7.1B
Viking Therapeutics is involved in developing treatments for metabolic and endocrine disorders, including NASH, positioning it as a competitor to Terns Pharmaceuticals.
Galmed Pharmaceuticals
GLMD
Mkt Cap2.18M
Galmed Pharmaceuticals competes in the NASH treatment space, making it a direct competitor to Terns Pharmaceuticals with its focus on liver diseases.
Agios Pharmaceuticals
AGIO
Mkt Cap2.61B
Agios Pharmaceuticals, while focusing on cellular metabolism to treat diseases, has interests in liver diseases, indirectly competing with Terns Pharmaceuticals.
Enanta Pharmaceuticals
ENTA
Mkt Cap272.91M
Enanta Pharmaceuticals is focused on liver diseases and respiratory infections, making it a competitor in the liver disease space, including NASH, where Terns is active.
FibroGen
FGEN
Mkt Cap36.71M
FibroGen focuses on the discovery, development, and commercialization of novel therapeutics, with a pipeline that could compete with Terns Pharmaceuticals in treating liver diseases.

Analyst Ratings

17.17$Average Price Target
The highest estimate is $26.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

About

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Show more...
CEO
Employees
66
Country
US
ISIN
US8808811074

Listings

F
DE
430.F
XNAS
US
TERN